drugset / Trial / NCT00227513

Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00227513

Phase 1 Completed 66 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of vorinostat and bortezomib in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more tumor cells.

Timeline

Start
2005-07
Primary completion
2010-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule Intravenous
Subject Vorinostat Small molecule Oral